DrugPatentWatch Database Preview
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
« Back to Dashboard
AG-120 is an investigational drug.
There have been 14 clinical trials for AG-120. The most recent clinical trial was a Phase 1 trial, which was initiated on December 1st 2016.
The most common disease conditions in clinical trials are Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, and Leukemia, Myeloid. The leading clinical trial sponsors are Agios Pharmaceuticals, Inc., Celgene Corporation, and Academic and Community Cancer Research United.
There are three US patents protecting this investigational drug and sixty-one international patents.
Recent Clinical Trials for AG-120
|Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma||National Cancer Institute (NCI)||Phase 1|
|Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma||Academic and Community Cancer Research United||Phase 1|
|A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS||Yale University||Phase 2|
Top disease conditions for AG-120
Top clinical trial sponsors for AG-120
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|AG-120||Start Trial||Therapeutically active compositions and their methods of use||Agios Pharmaceuticals, Inc. (Cambridge, MA)||Start Trial|
|AG-120||Start Trial||Therapeutically active compositions and their methods of use||AGIOS PHARMACEUTICALS, INC. (Cambridge, MA)||Start Trial|
|AG-120||Start Trial||Pharmaceutical compositions of therapeutically active compounds||AGIOS PHARMACEUTICALS, INC. (Cambridge, MA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|